Eli Lilly: Antibody combo works best on variants

INDIANAPOLIS (AP) — Drugmaker Eli Lilly says its COVID-19 antibody drug should no longer be given to patients alone because treatment combinations work better fighting some variants of the coronavirus. The company is asking U.S. regulators to revoke their emergency authorization for the use of bamlanivimab alone. Lilly says there are no new safety concerns with the drug, but the combination with another drug, etesevimab, fights more of the emerging COVID-19 variants in the U.S. Last November, bamlanivimab became the first antibody authorized for emergency use in the U.S. as a COVID-19 treatment.